These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38508835)

  • 1. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Mercuri E; Vilchez JJ; Boespflug-Tanguy O; Zaidman CM; Mah JK; Goemans N; Müller-Felber W; Niks EH; Schara-Schmidt U; Bertini E; Comi GP; Mathews KD; Servais L; Vandenborne K; Johannsen J; Messina S; Spinty S; McAdam L; Selby K; Byrne B; Laverty CG; Carroll K; Zardi G; Cazzaniga S; Coceani N; Bettica P; McDonald CM;
    Lancet Neurol; 2024 Apr; 23(4):393-403. PubMed ID: 38508835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Henzi BC; Schmidt S; Nagy S; Rubino-Nacht D; Schaedelin S; Putananickal N; Stimpson G; ; Amthor H; Childs AM; Deconinck N; de Groot I; Horrocks I; Houwen-van Opstal S; Laugel V; Lopez Lobato M; Madruga Garrido M; Nascimento Osorio A; Schara-Schmidt U; Spinty S; von Moers A; Lawrence F; Hafner P; Dorchies OM; Fischer D
    Lancet Neurol; 2023 Oct; 22(10):890-899. PubMed ID: 37739572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
    Buyse GM; Voit T; Schara U; Straathof CSM; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; McDonald CM; Rummey C; Meier T;
    Lancet; 2015 May; 385(9979):1748-1757. PubMed ID: 25907158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
    Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
    Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    McDonald CM; Marbán E; Hendrix S; Hogan N; Ruckdeschel Smith R; Eagle M; Finkel RS; Tian C; Janas J; Harmelink MM; Varadhachary AS; Taylor MD; Hor KN; Mayer OH; Henricson EK; Furlong P; Ascheim DD; Rogy S; Williams P; Marbán L;
    Lancet; 2022 Mar; 399(10329):1049-1058. PubMed ID: 35279258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
    Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
    Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
    Raman SV; Hor KN; Mazur W; Halnon NJ; Kissel JT; He X; Tran T; Smart S; McCarthy B; Taylor MD; Jefferies JL; Rafael-Fortney JA; Lowe J; Roble SL; Cripe LH
    Lancet Neurol; 2015 Feb; 14(2):153-61. PubMed ID: 25554404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
    Tawil R; Wagner KR; Hamel JI; Leung DG; Statland JM; Wang LH; Genge A; Sacconi S; Lochmüller H; Reyes-Leiva D; Diaz-Manera J; Alonso-Perez J; Muelas N; Vilchez JJ; Pestronk A; Gibson S; Goyal NA; Hayward LJ; Johnson N; LoRusso S; Freimer M; Shieh PB; Subramony SH; van Engelen B; Kools J; Leinhard OD; Widholm P; Morabito C; Moxham CM; Cadavid D; Mellion ML; Odueyungbo A; Tracewell WG; Accorsi A; Ronco L; Gould RJ; Shoskes J; Rojas LA; Jiang JG
    Lancet Neurol; 2024 May; 23(5):477-486. PubMed ID: 38631764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
    Knight EMP; Amin S; Bahi-Buisson N; Benke TA; Cross JH; Demarest ST; Olson HE; Specchio N; Fleming TR; Aimetti AA; Gasior M; Devinsky O;
    Lancet Neurol; 2022 May; 21(5):417-427. PubMed ID: 35429480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
    Mercuri E; Deconinck N; Mazzone ES; Nascimento A; Oskoui M; Saito K; Vuillerot C; Baranello G; Boespflug-Tanguy O; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Staunton H; Yeung WY; Martin C; Fontoura P; Day JW;
    Lancet Neurol; 2022 Jan; 21(1):42-52. PubMed ID: 34942136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.